has losartan been recalled 2019?
429532
In April 2019, Teva voluntarily recalled 35 lots of losartan potassium tablets (6 lots of 25 mg tablets, 29 lots of 100 mg tablets) due to detection of NMBA. In June 2019, Teva expanded the recall to include 6 additional lots (2 lots of 50 mg tablets and 4 lots of 100 mg tablets).
620249
Additional prescription and over-the-counter ranitidine drugs, including Zantac, are being recalled by Sanofi Consumer Health Inc., Sivem Pharmaceuticals ULC and Teva Canada Limited because they may contain the impurity N-nitrosodimethylamine (NDMA) above acceptable levels.
1338650
Unichem Laboratories is recalling 96,876 bottles of Bisoprolol Fumarate tablets used for the treatment of hypertension from the US market. Unichem Pharmaceuticals USA Inc is recalling the tablets in the strength of 5 mg manufactured by Unichem Laboratories at its Goa plant, USFDA said in its latest Enforcement Report.
448920
Recall: Generic Lisinopril for High Blood Pressure. Manufacturer Wockhardt has issued a voluntary recall of four lots of generic lisinopril (Zestril, Prinivil), an ACE inhibitor used to help lower blood pressure and treat heart failure.
572984
Update [12/18/2019] FDA is alerting patients and health care professionals to Glenmark Pharmaceutical Inc.'s voluntary recall of prescription ranitidine tablets (150 mg and 300 mg). The medicines are being recalled because they may contain unacceptable levels of N-nitrosodimethylamine (NDMA).
1343350
UPDATE: October 30, 2019 Ranbaxy Pharmaceuticals Canada Inc. is recalling all lots of its prescription ranitidine products from the Canadian market as a precautionary measure.
493513
The valsartan recall includes several, but not all, generic drugs that contain valsartan as the active ingredient. The recall does not currently include the brand name valsartan-containing drugs Diovan, Entresto, Exforge, and Exforge HCT.
1353521
Interactions between your drugs No interactions were found between Allergy Relief and losartan. This does not necessarily mean no interactions exist. Always consult your healthcare provider.
765039
FDA on Friday announced Sandoz has voluntarily recalled one lot of its blood pressure drug Hyzaar, after tablets from the lot tested positive for an impurity believed to cause cancer.
436601
The recall comes amid a larger string of recalls of blood pressure medications valsartan, losartan and irbesartan that contain trace levels of carcinogens NMBA, N-Nitrosodimethylamine (NDMA) and N-Nitrosodiethylamine (NDEA), the FDA says. Hundreds of lots of the medication have been recalled since last July.
891240
GSK recalls Paxil after FDA issues warning letter. GlaxoSmithKline has said it will recall some batches of its antidepressants Paxil and Seroxat because the active ingredient used to make them might have been tainted.
302518
Yes. Because ARBs treat serious medical conditions, continue taking your current medicine until a doctor or pharmacist gives you a replacement or a different treatment option. Remember, not all ARBs are being recalled, and not all lots of valsartan, irbesartan, and losartan are affected and being recalled.
569159
Dozens of blood pressure medications have been recalled since the first products were pulled off the shelf in July 2018 due to impurities. The affected products all contained valsartan, losartan, or irbesartan.
621826
Following a report of a metal contaminant found in a tablet, Lupin Pharmaceuticals Inc. is pulling 11,706 bottles of 10-mg lisinopril tablets, USP. The recall appears in the August 22, 2018, US Food and Drug Administration (FDA) Enforcement Report.
1229882
OTTAWA - Health Canada is advising Canadians that Pro Doc Limitée is voluntarily recalling two lots of irbesartan tablets because of a nitrosamine impurity, N-nitrosodiethylamine (NDEA). ... NDEA is classified as a probable human carcinogen, which means that long-term exposure could increase the potential risk of cancer.
131222
June 26: Macleods Pharmaceuticals recalls 32 lots of losartan potassium tablets and losartan potassium/hydrochlorothiazide tablets. ... June 16: Lupin Pharmaceuticals recalls 18,408 bottles of an antibiotic from the U.S. market.
697195
Sanofi US has voluntarily recalled all Auvi-Q® (epinephrine injection, USP) on the market through October 28, 2015. This includes both the 0.15 mg and 0.3 mg strengths for hospitals, retailers and consumers and covers lot numbers 2081278 through 3037230, which expire October 2015 through December 2016.